NASH is a common and progressive chronic liver disease that is an advanced progression of nonalcoholic fatty liver disease, or NAFLD.
Non-alcoholic steatohepatitis (NASH) is a common and progressive chronic liver disease that is an advanced progression of nonalcoholic fatty liver disease, or NAFLD. NASH has four main components.
The first component is metabolic. NASH is increasingly understood as the expression in the liver of metabolic syndrome and insulin sensitivity and is frequently associated with obesity, insulin resistance and type 2 diabetes.
Second, NASH is characterized by excessive fat accumulation in the liver, known as steatosis, that is not caused by excessive use of alcohol. Steatosis is a metabolic dysfunction that occurs when the liver cells import more fatty acids than they can metabolize, leading to lipogenesis, or the creation of fat.
Third, in NASH patients, steatosis induces chronic inflammation and the death of liver cells, observed histologically as ballooning of necrotic cells.
Fourth, inflammation and ballooning may lead to progressive fibrosis in the liver, and ultimately cirrhosis, as the body responds to the liver’s injured state by producing stellate cells, fibroblasts and accompanying proteins, such as collagen and fibronectin.
NASH is diagnosed by means of a liver biopsy that confirms the presence of steatosis, inflammation, ballooning and fibrosis.
The overall NASH prevalence in the adult population of the United States is believed to be approximately 12%. However, given the prevalence of the underlying risk factors for the disease, including type 2 diabetes and obesity, as well as the need for a biopsy to diagnose NASH, we believe that the disease may be underdiagnosed. By 2020, NASH is expected to become a leading cause of liver transplantation in the United States.
Additionally, NASH is now considered to be the leading, and a rapidly increasing, cause of hepatocellular carcinoma, or primary liver cancer, of which up to 40% of cases in NASH patients develop prior to developing cirrhosis. More than 20% of patients with NASH progress to cirrhosis within a decade of diagnosis and, compared to the general population, have a ten-fold greater risk of liver-related mortality.
There are currently no approved therapies for the treatment of NASH. For more insight into the disease please visit the panNASH Initiative website.
The overall NASH prevalence in the adult population of the United States is believed to be approximately 12%.
By 2020, NASH is expected to become a leading cause of liver transplantation in the United States.
A liver biopsy is a procedure performed in hospital or outpatient centres under local anaesthetic. The entire procedure takes a few minutes and is generally regarded as very safe. A small incision is made in the upper abdomen and a fine needle is inserted into the liver to remove a small amount of liver tissue. The patient will take a couple of hours to recover after the procedure and will then be allowed to go home. The liver sample is then analysed in a laboratory to look for changes to the appearance of the tissue indicating the presence or absence of NASH. The specialists will look for steatosis, inflammation, liver cell injury, fibrosis, and architectural remodelling which will provide information regarding the stage and severity of the disease.
Currently, there are no non-invasive tests available for a reliable diagnosis.
NASH is a silent disease which means that many affected patients are not aware that they are suffering from NASH. They do not experience pain nor do they necessarily have abnormal liver enzymes. The American Association for The Study of Liver Diseases (AASLD) therefore recommends generally testing patients who are at risk of having NASH*. Those patients typically suffer from diabetes, obesity, cardiovascular disease and carry additional risk factors such as age or ethnicity.
Because liver enzymes are normal in 60% of NASH patients, a liver biopsy is required to properly diagnose NASH.
An initiative has been launched, supported by Inventiva, to educate people and raise awareness about NASH: The NASH Education Program.
* American Association for The Study of Liver Diseases practice guideline.
Lanifibranor – Our Solution
A number of experimental treatments for NASH are being tested in clinical trials. Among those treatments, lanifibranor, Inventiva’s drug candidate for the treatment of NASH stands out.
Lanifibranor belongs to the class of peroxisome proliferator-activated receptor (PPAR) agonists and activates the three subtypes α, δ, and γ. PPARs are nuclear receptors responsible for the read out of certain genes involved in the regulation of metabolism and fibrotic processes. Due to its mechanism of action, lanifibranor has the potential to address all the key features of NASH: inflammation, steatosis, ballooning, and importantly fibrosis. This aspect of treating fibrosis is crucial as NASH patients with severe fibrosis are exposed to an increased risk of developing irreversible cirrhosis2.
Lanifibranor is currently being tested in a Phase IIb clinical trial for the treatment of NASH called NATIVE. The trial has completed enrolment. Headline results are expected in the first half of 2020.
In addition, Dr. Kenneth Cusi, Chief of the Division of Endocrinology, Diabetes & Metabolism in the Department of Medicine at the University of Florida, Gainesville, has selected lanifibranor for an investigator-initiated Phase II trial to evaluate the efficacy and safety of lanifibranor on intrahepatic triglycerides and hepatic insulin sensitivity in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD). The enrolment for this trial started in the second half of 2018. For a recording of a presentation on the study by Dr. Cusi and Pierre Broqua, CSO and co-founder of Inventiva, please click here.
Latest NASH News
1. European Association for the Study of the Liver. “Non-Alcoholic Fatty Liver Disease, Steatohepatitis: NASH linked to 50% higher death rate compared with NAFLD.” ScienceDaily. ScienceDaily, 24 April 2015.
2. American Association for The Study of Liver Diseases practice guideline.